Crestline Management LP increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 41.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,029 shares of the company’s stock after acquiring an additional 18,371 shares during the period. Neurocrine Biosciences comprises 0.5% of Crestline Management LP’s investment portfolio, making the stock its 23rd biggest holding. Crestline Management LP owned 0.07% of Neurocrine Biosciences worth $3,862,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Teacher Retirement System of Texas raised its holdings in shares of Neurocrine Biosciences by 0.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock worth $320,000 after acquiring an additional 57 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after buying an additional 193 shares during the last quarter. Utah Retirement Systems increased its stake in Neurocrine Biosciences by 1.9% in the 2nd quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock valued at $736,000 after buying an additional 300 shares during the last quarter. Aperio Group LLC increased its stake in Neurocrine Biosciences by 3.7% in the 2nd quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock valued at $1,027,000 after buying an additional 789 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock valued at $7,380,000 after buying an additional 810 shares during the last quarter.

NBIX has been the subject of several analyst reports. Piper Jaffray Companies set a $68.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, August 24th. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Oppenheimer reiterated a “buy” rating and issued a $70.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price objective on shares of Neurocrine Biosciences in a research note on Sunday, September 17th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $66.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $78.88.

In related news, insider Dimitri E. Grigoriadis sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the transaction, the insider now directly owns 77,691 shares of the company’s stock, valued at approximately $5,794,194.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Darin Lippoldt sold 6,279 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $75.04, for a total transaction of $471,176.16. Following the completion of the transaction, the insider now directly owns 19,436 shares of the company’s stock, valued at $1,458,477.44. The disclosure for this sale can be found here. Insiders have sold a total of 87,922 shares of company stock valued at $6,346,992 over the last three months. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $73.75 on Monday. Neurocrine Biosciences, Inc. has a 52-week low of $37.35 and a 52-week high of $75.98. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the company earned ($0.43) earnings per share. equities research analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Crestline Management LP Has $3.86 Million Position in Neurocrine Biosciences, Inc. (NBIX)” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/crestline-management-lp-has-3-86-million-position-in-neurocrine-biosciences-inc-nbix/1757072.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.